OCGN - Ocugen, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Malvern,
United States
Type: Equity
OCGN price evolution
OCGN
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $39.46 | $53.48 | $70.58 | $68.26 |
| Short term investments | $8.46 | |||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $42.97 | $56.56 | $73.45 | $84.4 |
| Long term investments | ||||
| Property, plant & equipment | $17.29 | $14.47 | $11.72 | $7.95 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $21.58 | $18.13 | $15.52 | $11.9 |
| Total investments | $8.46 | |||
| Total assets | $64.55 | $74.69 | $88.98 | $96.3 |
| Current liabilities | ||||
| Accounts payable | $3.17 | $2.92 | $3.88 | $8.09 |
| Deferred revenue | ||||
| Short long term debt | $0.57 | $1.82 | $1.79 | $1.77 |
| Total current liabilities | $17.09 | $11.14 | $13.46 | $15.68 |
| Long term debt | $6.37 | $4.66 | $4.78 | $4.51 |
| Total noncurrent liabilities | $6.89 | $5.16 | $5.24 | $4.82 |
| Total debt | $6.94 | $6.47 | $6.57 | $6.28 |
| Total liabilities | $23.98 | $16.29 | $18.7 | $20.5 |
| Shareholders' equity | ||||
| Retained earnings | -$286.17 | -$266.6 | -$252.44 | -$229.52 |
| Other shareholder equity | $0.02 | $0.03 | $0.02 | $0.03 |
| Total shareholder equity | $40.56 | $58.4 | $70.28 | $75.8 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $39.46 | $77.56 | $95.11 | $24.19 |
| Short term investments | $13.37 | |||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $42.97 | $98.49 | $102.65 | $25.88 |
| Long term investments | ||||
| Property, plant & equipment | $17.29 | $9.96 | $1.16 | $0.63 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $21.58 | $10.14 | $3.12 | $1.5 |
| Total investments | $13.37 | |||
| Total assets | $64.55 | $108.63 | $105.76 | $27.38 |
| Current liabilities | ||||
| Accounts payable | $3.17 | $8.06 | $2.31 | $0.4 |
| Deferred revenue | ||||
| Short long term debt | $0.57 | $0.5 | $0.36 | $0.28 |
| Total current liabilities | $17.09 | $18.46 | $7 | $3.61 |
| Long term debt | $6.37 | $2.29 | $2.94 | $2.21 |
| Total noncurrent liabilities | $6.89 | $6.12 | $2.94 | $2.21 |
| Total debt | $6.94 | $6.37 | $3.31 | $2.49 |
| Total liabilities | $23.98 | $24.58 | $9.94 | $5.83 |
| Shareholders' equity | ||||
| Retained earnings | -$286.17 | -$213.02 | -$131.67 | -$73.3 |
| Other shareholder equity | $0.02 | $0.03 | -$0.05 | |
| Total shareholder equity | $40.56 | $84.05 | $95.82 | $21.55 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6.04 | |||
| Cost of revenue | ||||
| Gross Profit | $6.04 | |||
| Operating activities | ||||
| Research & development | $9.5 | $6.34 | $14.17 | $9.56 |
| Selling, general & administrative | $5.16 | $9.08 | $9.56 | $8.19 |
| Total operating expenses | $14.66 | $15.42 | $23.73 | $17.75 |
| Operating income | -$8.62 | -$15.42 | -$23.73 | -$17.75 |
| Income from continuing operations | ||||
| EBIT | -$9.49 | -$14.16 | -$22.93 | -$16.5 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$9.49 | -$14.16 | -$22.93 | -$16.5 |
| Income (for common shares) | -$9.49 | -$14.16 | -$22.93 | -$16.5 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6.04 | $0.04 | ||
| Cost of revenue | ||||
| Gross Profit | $6.04 | $0.04 | ||
| Operating activities | ||||
| Research & development | $39.57 | $49.76 | $35.11 | $6.35 |
| Selling, general & administrative | $31.99 | $35.11 | $22.92 | $7.97 |
| Total operating expenses | $71.57 | $84.87 | $58.03 | $21.33 |
| Operating income | -$65.53 | -$84.87 | -$58.03 | -$21.28 |
| Income from continuing operations | ||||
| EBIT | -$63.08 | -$81.35 | -$58.34 | -$21.1 |
| Income tax expense | -$0.05 | |||
| Interest expense | $0.08 | $0.72 | ||
| Net income | ||||
| Net income | -$63.08 | -$81.35 | -$58.37 | -$21.82 |
| Income (for common shares) | -$63.08 | -$81.35 | -$58.37 | -$34.37 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$9.49 | -$14.16 | -$22.93 | -$16.5 |
| Operating activities | ||||
| Depreciation | $0.32 | $0.31 | $0.31 | $0.3 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.72 | $2.17 | $2.63 | $2.69 |
| Total cash flows from operations | -$11.3 | -$13.71 | -$18.81 | -$18.24 |
| Investing activities | ||||
| Capital expenditures | -$2.72 | -$3.37 | -$2.78 | -$1.61 |
| Investments | $8.5 | $5.05 | ||
| Total cash flows from investing | -$2.72 | -$3.37 | $5.72 | $3.44 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.02 | -$0.04 | $14.91 | $5.56 |
| Net borrowings | $0.49 | -$0.06 | ||
| Total cash flows from financing | $0.02 | -$0.04 | $15.4 | $5.5 |
| Effect of exchange rate | -$0.01 | $0.01 | -$0 | -$0 |
| Change in cash and equivalents | -$14.02 | -$17.1 | $2.32 | -$9.3 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$63.08 | -$81.35 | -$58.37 | -$21.82 |
| Operating activities | ||||
| Depreciation | $1.24 | $1.07 | $0.59 | $0.29 |
| Business acquisitions & disposals | -$0.13 | |||
| Stock-based compensation | $9.22 | $10.54 | $6.96 | $0.66 |
| Total cash flows from operations | -$62.05 | -$60.08 | -$47.94 | -$14.71 |
| Investing activities | ||||
| Capital expenditures | -$10.48 | -$4.46 | -$0.94 | -$0.31 |
| Investments | $13.55 | -$12.51 | ||
| Total cash flows from investing | $3.08 | -$16.97 | -$1.82 | -$0.31 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $20.45 | $59.02 | $120.69 | $36.34 |
| Net borrowings | $0.43 | $0.46 | -$0.01 | -$4.73 |
| Total cash flows from financing | $20.88 | $59.48 | $120.68 | $31.61 |
| Effect of exchange rate | -$0.01 | $0.03 | ||
| Change in cash and equivalents | -$38.1 | -$17.55 | $70.92 | $16.6 |
News
|
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Ocugen, Inc....
Investing.com
11 Apr 2024
|
|
Ocugen stock gains says EU backs U.S. trial for gene therapy
Seeking Alpha
10 Apr 2024
|
|
Ocugen's gene therapy OCU400 advances in Europe
Investing.com
10 Apr 2024
|
|
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
Zacks via Yahoo Finance
8 Apr 2024
|
|
Why Ocugen Stock Is Climbing Today - Ocugen (NASDAQ:OCGN)
Benzinga
5 Apr 2024
|
|
Ocugen advances to mid-dose trial for eye disease therapy
Investing.com
5 Apr 2024
|
|
Ocugen stock gains as study for eye disease therapy advances
Seeking Alpha
5 Apr 2024
|
|
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher...
Benzinga
3 Apr 2024
|
|
Why Ocugen Shares Are Popping Off - Ocugen (NASDAQ:OCGN)
Benzinga
3 Apr 2024
|
|
Oxford Industries Posts Weak Results, Joins Applied Therapeutics And Other Big Stocks Moving Lower...
Benzinga
1 Apr 2024
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $6.04M |
|---|---|
| EBITDA | -$61.84M |
| EBIT | -$63.08M |
| Net Income | -$63.08M |
| Revenue Q/Q | InfinityT% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -77.75% |
| ROE | -102.97% |
| Debt/Equity | 0.59 |
|---|---|
| Net debt/EBITDA | 0.25 |
| Current ratio | 2.51 |
| Quick ratio | 2.51 |